163 results about "Sulfatase" patented technology

The invention provides a method of promoting neuronal plasticity in the CNS of a mammal, the method comprising administering to the CNS of the mammal an agent that reduces the inhibitory properties of chondroitin sulphate proteoglycans. Preferred agents are chondroitinases and sulfatases, e.g., chondroitinase ABC. Also provided are methods of identifying further agents.

The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject. A final aspect of the invention provides a method of treating a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising a rhASA and thereby obtaining a reduction in the galactosyl sulphatide levels in target cells within said subject.

This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.

Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A.

A novel class of gonane type and D-homo-gonane type steroids having sulfatase-inhibiting and/or estrogenic activity is presented for application in the pharmaceutical industry. The number and location of sulfamoyloxy groups on the steroids provides for sulfatase inhibiting and estrogenic activities that independently vary over a wide range, allowing the customization of the pharmaceutical for specific purposes, including treatment and diagnosis of estrogen-dependent tumors.

Disclosed is a modified iduronate-2-sulfatase (IDS) gene constructed by inserting the nucleotide of SEQ ID NO: 2 into a wild-type IDS gene. In addition to being negatively charged, the improved IDS enzyme encoded by the modified gene exhibits a sufficient retention time in blood to target the bone, so that it is more effective for treating Hunter syndrome.

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

The present invention provides, among other things, compositions, kits and methods for subcutaneous delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention provides methods for treating Hunter syndrome by subcutaneous administration of a replacement iduronate-2-sulfatase (I2S) protein. In some embodiments, the present invention provides a kit comprising an arrangement of components for subcutaneously administering iduronate-2-sulfatase (I2S) protein.

A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also disclosed is a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye, said method comprising the step of contacting at least one hemorrhage-clearing enzyme (e.g., a β-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase or protein kinase) with the vitreous humor in an amount which is effective to cause accelerated clearance of blood therefrom.

Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

The method for producing fucosan sulfatase by bacterium includes the following steps: inoculating the strain vibrio fluvialis into fermented broth culture medium containing seaweed powder, culturing for a period of time at a certain temp., then adding enzyme-extracting agent, making produced precipitated downward be deposited, making separation, finally freeze-drying so as to obtain the invented product which has two classes of endofucosan sulfatase and exofucosan sulfatase, and can be degraded to obtain its oligosaccharide, disaccharide and monosaccharide. Said enzyme product has high activity and good stability.

The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form.

The invention discloses engineering colon bacillus for preparing intermediate carbon fatty alcohol and a method for preparing the intermediate carbon fatty alcohol. According to the method, the colon bacillus obtains a capability of producing biological gasoline by excessively expressing sulfatase genes, fatty acyl-CoA reductase genes and fatty aldehyde decarboxylase and the like in the colon bacillus, and the biological gasoline producing capability of the engineering colon bacillus is further improved by combining the excessively expressed acetyl-CoA carboxylase genes and knocking out the fatty acyl-CoA dehydrogenase genes of the colon bacillus. The method can be used for producing the new generation biological gasoline.

The invention provides an Ascophyllum Nodosum oligosaccharide preparation method and application of Ascophyllum Nodosum oligosaccharide to medicines for reducing blood sugar. The preparation method is characterized by including a technological process of taking degreased, deproteinized and depigmented Ascophyllum Nodosum fucoidin as a raw material, combining microwave-assisted treatment, adding pectinase, cellulose, fucoidanase and sulfatase to subject the fucoidin to enzymolysis, removing the fucoidin not degraded sufficiently and zymoprotein through ethanol precipitation, centrifuging liquid supernatant prior to distillation and concentration, blending the distilled and concentrated liquid supernatant with oligosaccharide generated during polysaccharide extraction prior to sieving by a molecular sieve, and subjecting interception matters to freeze drying so as to obtain the Ascophyllum Nodosum oligosaccharide, wherein ethanol used during preparation is recycled. Through in-vitro and cell tests, the Ascophyllum Nodosum oligosaccharide has a remarkable improvement effect on glycometabolism. The preparation method is an efficient and environment-friendly technological method for preparing the Ascophyllum Nodosum oligosaccharide by microwave-accelerated enzymatic digestion.

The invention discloses an aryl sulfatase gene, a protein encoded by the aryl sulfatase gene as well as an immobilization method and application of the protein. The immobilization method and application comprise the following steps of firstly expressing the aryl sulfatase gene of pseudoalteromonas carrageenovora sp in escherichia coli and purifying to obtain a recombinant aryl sulfatase; by adopting carboxyl-functionalized Fe3O4 magnetic nanoparticles as carriers and glutaraldehyde as a cross-linking reagent and immobilizing the free recombinant aryl sulfatase to obtain the immobilized recombinant aryl sulfatase; treating agar with the immobilized recombinant aryl sulfatase, carrying out shaking reaction for 1 hour at 40 DEG C and measuring the physical properties of agar such as gel strength, the content of sulfate groups and the like. The immobilized recombinant aryl sulfatase disclosed by the invention can be repeatedly used, still maintains more than 60% of the enzyme activity after being repeatedly used for eight times and shows good operating stability and feasibility of practical application.